Pieris Pharmaceuticals Newsroom

Pieris Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

SECNov 14 05:09 · Announcements

Pieris Pharmaceuticals' Merger Target Palvella Doses First Patient in Phase 3 Trial of Lymphatic Drug

MT NewswiresNov 8 00:48

Express News | Palvella Therapeutics Announces First Patient Dosed in Selva Phase 3 Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

BreakingsNov 7 21:30

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

GlobeNewswireNov 7 21:30

Express News | Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

BreakingsOct 17 19:30

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

GlobeNewswireOct 15 19:30

Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

BenzingaOct 3 19:42

Palvella Therapeutics Awarded Up to $2.6 Million Grant From the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

GlobeNewswireOct 3 19:30

Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 Loss per Share (Vs US$3.63 Profit in 2Q 2023)

Yahoo FinanceAug 19 18:07

We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate

Yahoo FinanceAug 17 21:10

Pieris Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

SECAug 15 04:53 · Announcements

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.

PR NewswireJul 25 05:03

Shareholder Alert: Ademi LLP Investigates Whether Pieris Pharmaceuticals, Inc. Has Obtained a Fair Price for Its Public Shareholders

PRNewswireJul 25 02:55

Trending Stocks Today | Nuzee Surges 273.78%

July 24th - US stocks trending in regular trading hours.Gainers: $Nuzee(NUZE.US)$ shoots up 273.78% to $3.85 with a turnover of $404.63 million. $Dermata Therapeutics(DRMA.US)$ soars 122.31% to $2.89

Futu NewsJul 25 02:00

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT NewswiresJul 25 01:53

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

BenzingaJul 25 01:26

Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results

BenzingaJul 25 00:30

Pieris Pharma Surges on All-stock Merger Deal

Seeking AlphaJul 24 22:39

Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics

WSJJul 24 21:54

Pieris Pharmaceuticals Shares Resume Trade

BenzingaJul 24 21:40